Alvea Updates /
Alvea Wind Down Announcement
After careful consideration, we made the difficult decision to wind Alvea down and return our remaining funds to investors. This decision was the result of many months of experimentation and analysis regarding Alvea’s strategy, path to impact, and commercial potential, which ultimately led us to the conclusion that Alvea’s overall prospects were not sufficiently compelling […]
Alvea Set the Record for Fastest Startup to Take a New Drug into a Phase 1 Clinical Trial, from Founding to First-in-Human
From Founding to Clinical Trial in 28 Weeks After reviewing every Phase 1 clinical trial in the last 35 years, we found that our time from startup formation to first patient dosing (196 days) was faster than any other startup on record has ever taken a new drug into the clinic. Alvea’s plasmid DNA Omicron […]
Lessons from Developing a COVID Vaccine
Alvea’s CEO, Grigory Khimulya, reflects on lessons from the first six months of Alvea’s effort to bring a shelf-stable COVID-19 Omicron vaccine from idea to patients. He discusses inefficiencies in the clinical development process, what make’s Alvea’s culture and approach to clinical development different, and takes questions from the audience on a range of topics.
In the Press /
Alvea Launches Scalable, Shelf- Stable DNA Vaccine Development against New SARS-CoV-2 Variants 2
Breakthrough DNA vaccine, Alveavax, enters pre-clinical testing for Omicron & BA.2 variants. Alvea, a startup biotechnology company, today announced that it will begin to develop, test, and deliver DNA vaccines at scale to low and middle income countries with limited access to existing vaccine options.